Frederick L Altice

Summary

Publications

  1. pmc Adherence to hepatitis B virus vaccination at syringe exchange sites
    Frederick L Altice
    Yale University AIDS Program, 135 College Street, Suite 323, New Haven, CT 06510 2283, USA
    J Urban Health 82:151-61. 2005
  2. pmc Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial
    Frederick L Altice
    Yale University AIDS Program, Yale University, New Haven, CT 06510 2283, USA
    Clin Infect Dis 45:770-8. 2007
  3. pmc Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy
    Duncan Smith Rohrberg Maru
    Yale University AIDS Program, 135 College Street, Suite 323, New Haven, CT 06510 2283, USA
    AIDS Behav 12:284-93. 2008
  4. pmc Antiretroviral treatment regimen outcomes among HIV-infected prisoners
    Sandra A Springer
    Yale University AIDS Program, New Haven, CT 06510 2283, USA
    HIV Clin Trials 8:205-12. 2007
  5. doi request reprint Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs
    Frederick L Altice
    Department of Medicine, Section of Infectious Diseases, Yale University, New Haven, CT 06510 2283, USA
    Lancet 376:367-87. 2010
  6. pmc Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market
    R Douglas Bruce
    Yale University AIDS Program, New Haven, Connecticut, USA
    Am J Drug Alcohol Abuse 35:68-72. 2009
  7. ncbi request reprint Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication
    Frederick L Altice
    Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut 06510 2283, USA
    Clin Infect Dis 38:S376-87. 2004
  8. ncbi request reprint Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir
    Robert Douglas Bruce
    Department of Medicine, Yale University AIDS Program, New Haven, CT, USA
    J Acquir Immune Defic Syndr 54:511-4. 2010
  9. pmc Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trial
    Duncan Smith Rohrberg Maru
    Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, CT, USA
    J Acquir Immune Defic Syndr 50:176-81. 2009
  10. pmc HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications
    R Douglas Bruce
    Yale University AIDS Program, New Haven, CT 06510 2283, United States
    Int J Drug Policy 18:326-8. 2007

Collaborators

Detail Information

Publications69

  1. pmc Adherence to hepatitis B virus vaccination at syringe exchange sites
    Frederick L Altice
    Yale University AIDS Program, 135 College Street, Suite 323, New Haven, CT 06510 2283, USA
    J Urban Health 82:151-61. 2005
    ..Trust engendered by and mutual respect afforded by such programs result in repeated encounters by active IDUs over time...
  2. pmc Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial
    Frederick L Altice
    Yale University AIDS Program, Yale University, New Haven, CT 06510 2283, USA
    Clin Infect Dis 45:770-8. 2007
    ..Directly administered antiretroviral therapy (DAART) is one approach to improve treatment adherence among human immunodeficiency virus (HIV)-infected drug users...
  3. pmc Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy
    Duncan Smith Rohrberg Maru
    Yale University AIDS Program, 135 College Street, Suite 323, New Haven, CT 06510 2283, USA
    AIDS Behav 12:284-93. 2008
    ..The presence of depression and the lack of willingness to travel greater than four blocks to receive DAART predicted time-to-discontinuation...
  4. pmc Antiretroviral treatment regimen outcomes among HIV-infected prisoners
    Sandra A Springer
    Yale University AIDS Program, New Haven, CT 06510 2283, USA
    HIV Clin Trials 8:205-12. 2007
    ..Despite the high prevalence of HIV in correctional settings, the duration of therapy and response to various highly active antiretroviral therapy (HAART) regimens in this setting is unknown...
  5. doi request reprint Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs
    Frederick L Altice
    Department of Medicine, Section of Infectious Diseases, Yale University, New Haven, CT 06510 2283, USA
    Lancet 376:367-87. 2010
    ..Multifaceted, interdisciplinary approaches are urgently needed to achieve parity in health outcomes in HIV-infected drug users...
  6. pmc Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market
    R Douglas Bruce
    Yale University AIDS Program, New Haven, Connecticut, USA
    Am J Drug Alcohol Abuse 35:68-72. 2009
    ..To address this concern, co-formulation of buprenorphine/naloxone (BPN/NLX) replaced buprenorphine alone in Malaysia in December 2006...
  7. ncbi request reprint Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication
    Frederick L Altice
    Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut 06510 2283, USA
    Clin Infect Dis 38:S376-87. 2004
    ..Moreover, DAART should incorporate enhanced elements such as convenience, flexibility, confidentiality, cues and reminders, responsive pharmacy and medical services, and specialized training for staff...
  8. ncbi request reprint Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir
    Robert Douglas Bruce
    Department of Medicine, Yale University AIDS Program, New Haven, CT, USA
    J Acquir Immune Defic Syndr 54:511-4. 2010
    ..This study was conducted to examine the pharmacokinetic interactions between buprenorphine/naloxone (BUP/NLX) and lopinavir/ritonavir (LPV/r) in HIV-seronegative subjects chronically maintained on BUP/NLX...
  9. pmc Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trial
    Duncan Smith Rohrberg Maru
    Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, CT, USA
    J Acquir Immune Defic Syndr 50:176-81. 2009
    ....
  10. pmc HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications
    R Douglas Bruce
    Yale University AIDS Program, New Haven, CT 06510 2283, United States
    Int J Drug Policy 18:326-8. 2007
    ..Until buprenorphine maintenance therapy (BMT) was introduced, few effective strategies aimed at achieving reduction in illicit drug use were available as a conduit to anti-retroviral therapy (ARV) among IDUs...
  11. doi request reprint Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication
    R Douglas Bruce
    Yale University AIDS Program, New Haven, CT 06510, USA
    Am J Drug Alcohol Abuse 38:206-12. 2012
    ....
  12. pmc Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment
    SANDRA ANN SPRINGER
    Yale AIDS Program, 135 College Street, Suite 323, New Haven, CT 06510, USA
    J Urban Health 87:592-602. 2010
    ..Future randomized controlled trials are needed to affirm its benefit in this highly vulnerable population...
  13. doi request reprint A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice
    R Douglas Bruce
    Yale University AIDS Program, New Haven, CT, USA
    Expert Rev Clin Pharmacol 6:249-69. 2013
    ..Drug interactions between methadone, buprenorphine and HIV medications are known and may have important clinical consequences. Clinicians must be alert to these interactions and have a basic knowledge regarding their management...
  14. pmc Frequent emergency department use among released prisoners with human immunodeficiency virus: characterization including a novel multimorbidity index
    Jaimie P Meyer
    Department of Medicine, Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, CT, USA
    Acad Emerg Med 20:79-88. 2013
    ..The objective was to characterize the medical, social, and psychiatric correlates of frequent emergency department (ED) use among released prisoners with human immunodeficiency virus (HIV)...
  15. pmc Attitudes toward opioid substitution therapy and pre-incarceration HIV transmission behaviors among HIV-infected prisoners in Malaysia: implications for secondary prevention
    Chethan Bachireddy
    Department of Medicine, Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, CT 06510, USA
    Drug Alcohol Depend 116:151-7. 2011
    ..Pre-incarceration HIV transmission behaviors and current attitudes toward opioid substitution therapy (OST) among HIV-infected male prisoners in Malaysia have important implications for secondary HIV prevention efforts...
  16. pmc Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users
    Frederick L Altice
    Yale University AIDS Program, New Haven, Connecticut 06510, USA
    J Urban Health 80:416-27. 2003
    ..In addition, it demonstrates that this population can benefit from this therapy with the support of a nontraditional, community-based health intervention...
  17. pmc Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
    R Douglas Bruce
    Yale University AIDS Program, 135 College Street, Suite 323, New Haven, CT, United States
    Drug Alcohol Depend 105:234-9. 2009
    ..BUP/NLX and TPV/r should therefore be used cautiously to avoid decreased efficacy of TPV in patients taking these agents concomitantly...
  18. ncbi request reprint Impact of enhanced services on virologic outcomes in a directly administered antiretroviral therapy trial for HIV-infected drug users
    Duncan Smith-Rohrberg
    Yale University AIDS Program, New Haven, Connecticut 06510 2283, USA
    J Acquir Immune Defic Syndr 43:S48-53. 2006
    ....
  19. pmc Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: results from a randomized controlled trial
    Duncan Smith Rohrberg Maru
    Yale University AIDS Program, Yale University School of Medicine, New Haven, CT 06510 2283, USA
    J Acquir Immune Defic Syndr 46:555-63. 2007
    ..Directly administered antiretroviral therapy (DAART) is an effective intervention that improves clinical outcomes among HIV-infected drug users. Its effects on antiretroviral drug resistance, however, are unknown...
  20. pmc HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study
    Frederick L Altice
    Yale University School of Medicine, New Haven, CT, USA
    J Acquir Immune Defic Syndr 56:S22-32. 2011
    ..Having opioid dependence and HIV infection are associated with poor HIV-related treatment outcomes...
  21. pmc Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone
    David A Fiellin
    Departments of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520 8093, USA
    J Acquir Immune Defic Syndr 56:S33-8. 2011
    ..Buprenorphine/naloxone allows the integration of opioid dependence and HIV treatment...
  22. pmc Contribution of substance use disorders on HIV treatment outcomes and antiretroviral medication adherence among HIV-infected persons entering jail
    Ehsan Chitsaz
    Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, 135 College Street, Suite 323, New Haven, CT, 06510 2283, USA
    AIDS Behav 17:S118-27. 2013
    ..Evidence-based drug treatments that include multi-faceted interventions, including medication-assisted therapies, are urgently needed to effectively engage this vulnerable population...
  23. ncbi request reprint Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community
    Sandra A Springer
    Yale AIDS Program, Yale University School of Medicine, New Haven, Connecticut 06510 2283, USA
    Clin Infect Dis 38:1754-60. 2004
    ..More effective community-release programs are needed for incarcerated patients with HIV disease...
  24. pmc Correlates of HIV infection among incarcerated women: implications for improving detection of HIV infection
    Frederick L Altice
    Yale University, School of Medecine, New Haven, CT 06510 2283, USA
    J Urban Health 82:312-26. 2005
    ..Alternative methods of facilitating more widespread HIV testing, such as saliva tests, rapid serologic tests, and more routine testing in high HIV-prevalence areas should be considered both for clinical and for public health benefits...
  25. doi request reprint Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations
    Duncan Smith Rohrberg Maru
    Yale AIDS Program, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Infect Dis 47:952-61. 2008
    ..Data are lacking on outcomes of treatment with pegylated interferon plus ribavirin (PEG-RBV) in correctional settings...
  26. pmc Substance abuse, violence, and HIV in women: a literature review of the syndemic
    Jaimie P Meyer
    Yale University School of Medicine, AIDS Program, New Haven, CT 06510 2283, USA
    J Womens Health (Larchmt) 20:991-1006. 2011
    ..Development and adaptation of evidence-based interventions that incorporate prevention of violence and management of victimization to target this vulnerable group of women and thereby promote better health outcomes are urgently needed...
  27. doi request reprint Understanding the revolving door: individual and structural-level predictors of recidivism among individuals with HIV leaving jail
    Jeannia J Fu
    Section of Infectious Diseases, AIDS Program, Department of Internal Medicine, Yale School of Medicine, 135 College Street, Suite 323, New Haven, CT, 06510, USA
    AIDS Behav 17:S145-55. 2013
    ..Reducing criminal justice involvement should be a key component of efforts to promote more sustainable improvements in health and well-being among individuals living with HIV...
  28. pmc Public health implications for adequate transitional care for HIV-infected prisoners: five essential components
    Sandra A Springer
    AIDS Program, Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut 06511, USA
    Clin Infect Dis 53:469-79. 2011
    ....
  29. pmc A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization
    Marwan M Azar
    Yale University School of Medicine, Department of Medicine, Section of Infectious Diseases, AIDS Program, 135 College Street, Suite 323, New Haven 06511, CT, USA
    Drug Alcohol Depend 112:178-93. 2010
    ..Alcohol use disorders (AUDs) are highly prevalent and associated with non-adherence to antiretroviral therapy, decreased health care utilization and poor HIV treatment outcomes among HIV-infected individuals...
  30. pmc HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners
    Sandra A Springer
    Yale University School of Medicine, Department of Medicine, Section of Infectious Diseases, AIDS Program, 135 College Street, Suite 323, New Haven, CT 06511, USA
    Am J Drug Alcohol Abuse 37:12-21. 2011
    ....
  31. doi request reprint Comparison of tuberculin skin testing reactivity in opioid-dependent patients seeking treatment with methadone versus buprenorphine: policy implications for tuberculosis screening
    Ryan K Schwarz
    Department of Medicine, Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, Connecticut, USA
    Am J Drug Alcohol Abuse 35:439-44. 2009
    ..Currently, tuberculin skin testing (TST) is recommended for patients enrolling in methadone maintenance treatment (MMT), but not for those enrolling in buprenorphine maintenance treatment (BMT)...
  32. ncbi request reprint Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice
    R Douglas Bruce
    Yale University AIDS Program, 135 College Street, New Haven, CT 06511, USA
    J Acquir Immune Defic Syndr 41:563-72. 2006
    ..Global access to opioid agonist therapy and HIV treatment is expanding but when concurrently used, problematic pharmacokinetic drug interactions can occur...
  33. ncbi request reprint The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention
    Frederick L Altice
    AIDS Program, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT 06510, USA
    Clin Infect Dis 43:S178-83. 2006
    ..Dialogue among practitioners and policy makers in the HIV care and substance abuse communities will facilitate an effective expansion of buprenorphine and ensure that these beneficial outcomes are achieved...
  34. doi request reprint Case series of buprenorphine injectors in Kuala Lumpur, Malaysia
    R Douglas Bruce
    AIDS Program, Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut 06510 2283, USA
    Am J Drug Alcohol Abuse 34:511-7. 2008
    ..Prospective cohort studies, rather than hospital-derived samples, are needed to better understand the safety of buprenorphine injection...
  35. pmc Pharmacological pain control for human immunodeficiency virus-infected adults with a history of drug dependence
    Sanjay Basu
    Yale University AIDS Program, Yale University School of Medicine, New Haven, CT 06511, USA
    J Subst Abuse Treat 32:399-409. 2007
    ....
  36. pmc Clinical care of the HIV-infected drug user
    R Douglas Bruce
    Yale University AIDS Program, Yale University School of Medicine, New Haven, CT 06510, USA
    Infect Dis Clin North Am 21:149-79, ix. 2007
    ....
  37. ncbi request reprint Managing HIV/AIDS in correctional settings
    Sandra A Springer
    Yale University School of Medicine, Yale AIDS Program, Section of Infectious Diseases, 135 College Street, Suite 323, New Haven, CT 06510, USA
    Curr HIV/AIDS Rep 2:165-70. 2005
    ....
  38. ncbi request reprint Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases
    Robert D Bruce
    Yale University AIDS Program, New Haven, Connecticut 06511, USA
    Am J Drug Alcohol Abuse 33:869-74. 2007
    ..Previous reports in the literature have suggested hepatotoxicity with buprenorphine tempering initial enthusiasm of the safety of buprenorphine in HCV-infected patients...
  39. pmc Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services
    Laurie Sylla
    Yale University AIDS Programme, 135 College Street, Suite 323, New Haven, CT 06510, United States
    Int J Drug Policy 18:306-12. 2007
    ....
  40. pmc Implementing methadone maintenance treatment in prisons in Malaysia
    Jeffrey A Wickersham
    Yale University School of Medicine, Department of Medicine, Infectious Diseases Section, AIDS Program, 135 College Street Suite 323, New Haven, CT 06510 2283, USA
    Bull World Health Organ 91:124-9. 2013
    ..For this reason, the country undertook a three-phase roll-out of a methadone maintenance treatment (MMT) programme. In Phase 3, described in this paper, MMT was implemented within prisons and retention in care was assessed...
  41. pmc Methadone dose at the time of release from prison significantly influences retention in treatment: implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia
    Jeffrey A Wickersham
    Yale University School of Medicine, Department of Medicine, Infectious Diseases Section, AIDS Program, New Haven, CT 06510 2283, USA
    Drug Alcohol Depend 132:378-82. 2013
    ..To evaluate the impact of methadone dose on post-release retention in treatment among HIV-infected prisoners initiating methadone maintenance treatment (MMT) within prison...
  42. ncbi request reprint Observations on implementing routine HIV testing in jails
    Ravi Kavasery
    Yale University School of Medicine, Yale University AIDS Program, New Haven, Connecticut 06510 2283, USA
    AIDS Patient Care STDS 21:715-6; author reply 717. 2007
  43. ncbi request reprint Models for integrating buprenorphine therapy into the primary HIV care setting
    Sanjay Basu
    AIDS Program, Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Clin Infect Dis 42:716-21. 2006
    ..The key barriers against effective integration of buprenorphine maintenance therapy and primary HIV services are discussed, and we suggest several mechanisms to overcome such obstacles...
  44. pmc Hepatitis B virus infection in US correctional facilities: a review of diagnosis, management, and public health implications
    Shaili Gupta
    Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, CT 06510 2283, USA
    J Urban Health 86:263-79. 2009
    ..We present a review of diagnosis, prevention, and the recently streamlined treatment guidelines for management of HBV infection in correctional settings, and discuss the implications and public health impact of these measures...
  45. doi request reprint Preparing for highly active antiretroviral therapy rollout in rural South Africa: an assessment using the information, motivation, and behavioral skills model
    Margo D Simon
    AIDS Program, Yale University School of Medicine, New Haven, CT, USA
    AIDS Care 22:462-74. 2010
    ..Community-based assessments are urgently needed as HAART rollouts continue. Adaptation of this IMB-based survey may better inform efforts to enhance HAART-program implementation in resource-limited settings globally...
  46. pmc Latent tuberculosis infection: screening and treatment in an urban setting
    Jamie P Morano
    Department of Medicine, Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, 135 College Street, Suite 323, New Haven, CT 06510, USA
    J Community Health 38:941-50. 2013
    ..Within a diverse, urban environment, DOT and SAT IPT models for LTBI treatment resulted in similar outcomes, yet outcomes were hampered by differential measurement bias between DOT and SAT participants. ..
  47. pmc The burgeoning HIV/HCV syndemic in the urban Northeast: HCV, HIV, and HIV/HCV coinfection in an urban setting
    Jamie P Morano
    Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, Yale School of Medicine, New Haven, Connecticut, USA
    PLoS ONE 8:e64321. 2013
    ..S. still remain untested and undiagnosed. This cross-sectional study examines the correlates of HCV and HIV monoinfection and HIV/HCV coinfection in an urban Northeast setting...
  48. pmc Correlates of retention in HIV care after release from jail: results from a multi-site study
    Amy L Althoff
    AIDS Program, Yale University School of Medicine, 135 College Street, Suite 323, New Haven, CT, 06510, USA
    AIDS Behav 17:S156-70. 2013
    ..59, p = 0.02), HIV education (AOR 2.03, p ≤ 0.01), and transportation assistance (AOR 1.54, p = 0.02) after release. Provision of education and case management services improve retention in HIV care after release from jail...
  49. doi request reprint Patterns of homelessness and implications for HIV health after release from jail
    Alexei Zelenev
    Section of Infectious Diseases, AIDS Program, Department of Internal Medicine, Yale University School of Medicine, 135 College Street, Suite 323, New Haven, CT, 06510, USA
    AIDS Behav 17:S181-94. 2013
    ....
  50. pmc A systematic review of antiretroviral adherence interventions for HIV-infected people who use drugs
    Meredith Camp Binford
    Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, 135 College Street, Suite 323, New Haven, CT 06510 2283, USA
    Curr HIV/AIDS Rep 9:287-312. 2012
    ..Future research directions, including the development of interventions that promote long-term improvements in adherence and virologic outcomes, are discussed...
  51. doi request reprint Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence
    Ali S Saber-Tehrani
    Yale University AIDS Program, Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT 06510, USA
    Am J Drug Alcohol Abuse 37:1-11. 2011
    ..When medication-assisted treatment for opioid dependence is concurrently used with psychotropic medications, problematic pharmacokinetic drug interactions may occur...
  52. ncbi request reprint Attitudes toward and beliefs about prenatal HIV testing policies and mandatory HIV testing of newborns among drug users
    Odicie Fielder
    Yale University School of Medicine, New Haven, Connecticut, USA
    AIDS Public Policy J 20:74-91. 2005
    ..We also examined to what extent negative experiences and stigmatization affected attitudes toward HIV testing...
  53. ncbi request reprint Cost-effectiveness of HIV screening for incarcerated pregnant women
    Stephen Resch
    Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06510 2283, USA
    J Acquir Immune Defic Syndr 38:163-73. 2005
    ..In settings where HIV screening policies are not in place, however, the implementation of RPS can be expected to significantly reduce pediatric HIV cases and net health care expenditures...
  54. doi request reprint Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice
    R Douglas Bruce
    Yale University AIDS Program, 135 College Street, Suite 323, New Haven, CT 06511, USA
    Expert Rev Clin Pharmacol 1:115-27. 2008
    ..Moreover, there is considerable need for carefully controlled studies in this important and emerging area. ..
  55. pmc Integration of health services improves multiple healthcare outcomes among HIV-infected people who inject drugs in Ukraine
    Chethan Bachireddy
    Yale University School of Medicine, Department of Medicine, Section of Infectious Diseases, AIDS Program, New Haven, USA
    Drug Alcohol Depend 134:106-14. 2014
    ..We assess integrated/co-located (ICL) healthcare for HIV-infected PWID, which despite international recommendations, is neither widely available nor empirically examined...
  56. pmc Post-release substance abuse outcomes among HIV-infected jail detainees: results from a multisite study
    Archana Krishnan
    Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, 135 College St, Suite 323, New Haven, CT, 06510 2283, USA
    AIDS Behav 17:S171-80. 2013
    ....
  57. pmc Neurocognitive impairment and HIV risk factors: a reciprocal relationship
    Pria Anand
    Department of Medicine, Yale University School of Medicine, New Haven, CT 06510 2283, USA
    AIDS Behav 14:1213-26. 2010
    ..In order to be effective, risk-reduction interventions must therefore take into account the impact of cognitive impairment on learning and behavior...
  58. ncbi request reprint Human immunodeficiency virus infection with human granulocytic ehrlichiosis complicated by symptomatic lactic acidosis
    Sandra A Springer
    Yale University AIDS Program, Yale New Haven Hospital and Yale School of Medicine, New Haven, CT, 06510 2283, USA
    Clin Infect Dis 36:e162-4. 2003
    ..To date, this is the first presentation of symptomatic hyperlactatemia in a patient with HIV infection and HGE...
  59. pmc Being Unaware of Being HIV-Infected is Associated with Alcohol Use Disorders and High-Risk Sexual Behaviors Among Men Who have Sex with Men in Peru
    Panagiotis Vagenas
    Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, Yale University AIDS Program, 135 College Street, Suite 323, New Haven, CT, 06510, USA
    AIDS Behav 18:120-7. 2014
    ..Being unaware of being HIV-infected was associated with high-risk sexual behaviors and AUDs, both of which are amenable to behavioral and medication-assisted therapy interventions. ..
  60. pmc Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence
    Ryan Schwarz
    Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    J Subst Abuse Treat 43:451-7. 2012
    ..Overall, ED utilization was 0.93 events per person year and was significantly reduced by BMT, with increasing time (retention) on BMT. BMT had no significant effect on hospitalizations or average length of stay...
  61. ncbi request reprint Increasing drug users' adherence to HIV treatment: results of a peer-driven intervention feasibility study
    Robert S Broadhead
    Department of Sociology, University of Connecticut, Storrs 06269 2068, USA
    Soc Sci Med 55:235-46. 2002
    ..Innovative mechanisms that harness drug users' peer pressure to promote positive behavioral changes deserve greater study...
  62. ncbi request reprint Randomized, controlled trials of directly administered antiretroviral therapy for HIV-infected patients: questions about study population and analytical approach
    Duncan Smith-Rohrberg
    Clin Infect Dis 43:1221-2; author reply 1222-3. 2006
  63. pmc The impact of needle exchange-based health services on emergency department use
    Harold A Pollack
    School of Public Health, University of Michigan, Ann Arbor 48109 2029, USA
    J Gen Intern Med 17:341-8. 2002
    ....
  64. ncbi request reprint HIV testing in correctional institutions: evaluating existing strategies, setting new standards
    Sanjay Basu
    AIDS Program, Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, in New Haven, Connecticut, USA
    AIDS Public Policy J 20:3-24. 2005
    ..Jails present added complexities because of their shorter stay with respect to prisons, and testing, treatment, and counseling policies must be adapted to these settings...
  65. doi request reprint Strategies for primary HIV prevention that target behavioral change
    Steven A Safren
    Fenway Community Health and Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Infect Dis 45:S300-307. 2007
    ..Objective evidence of reductions in high-risk behavior in these 3 groups, which account for the majority of HIV transmissions in the United States, has critical implications for reducing the overall rate of new HIV infections...
  66. ncbi request reprint Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir
    R Douglas Bruce
    AIDS 20:783-4. 2006
  67. ncbi request reprint Editorial comment: why treat three conditions when it is one patient?
    R Douglas Bruce
    AIDS Read 13:378-9. 2003
  68. ncbi request reprint The association between history of violence and HIV risk: a cross-sectional study of HIV-negative incarcerated women in Connecticut
    Anita Ravi
    Atlanta, GA, USA
    Womens Health Issues 17:210-6. 2007
    ....
  69. ncbi request reprint HIV control efforts should directly address incarceration
    Duncan Smith Rohrberg Maru
    Lancet Infect Dis 7:568-9. 2007